Management of Breakthrough Bleeding in Continuous Combined Hormone‑Replacement Therapy

Initial Evaluation

Perform transvaginal ultrasound; if endometrial thickness > 5 mm or bleeding persists > 3 months, obtain an endometrial biopsy to exclude hyperplasia or malignancy. American College of Endocrinology/Endocrine Society guideline – Grade A. 1
Confirm a negative pregnancy test before any therapeutic change, as spontaneous ovulation can occur despite continuous combined HRT. Annales d’endocrinologie recommendation. 2

If breakthrough bleeding occurs after ≥3 months on estradiol 1 mg + norethindrone acetate 0.5 mg daily, increase norethindrone acetate to 1 mg daily to improve bleeding control while preserving endometrial protection. American College of Endocrinology/Endocrine Society guideline – Grade A. 1

Switch to transdermal estradiol 50 µg/day patch (changed twice weekly) plus oral micronized progesterone 200 mg nightly for 12–14 days each 28‑day cycle if bleeding persists after dose escalation or if the patient has cardiovascular/metabolic risk factors. American College of Endocrinology/Endocrine Society guideline – Grade A. 1
Micronized progesterone is the preferred progestin because it carries lower cardiovascular and venous‑thromboembolism risk than synthetic progestins such as norethindrone acetate. American College of Endocrinology/Endocrine Society guideline – Grade A. 1
Sequential micronized progesterone regimens produce predictable withdrawal bleeding 2–7 days after the last progesterone dose, which many patients find preferable to unpredictable breakthrough bleeding. American College of Endocrinology/Endocrine Society guideline – Grade A. 1
If oral progesterone causes intolerable sedation, mood changes, or bloating, use vaginal micronized progesterone 200 mg daily for 12–14 days per month; this route offers equivalent endometrial protection with fewer systemic side effects. American College of Endocrinology/Endocrine Society guideline – Grade A. 1

Transdermal estradiol 50 µg/day patch daily combined with oral micronized progesterone 100 mg daily continuously provides continuous endometrial protection; patients should be counseled that amenorrhea typically requires 6–12 months and that breakthrough bleeding is common during the first year. American College of Endocrinology/Endocrine Society guideline – Grade A. 1

Re‑evaluate bleeding pattern 3 months after any dose adjustment.
If breakthrough bleeding persists beyond 3 months on norethindrone acetate 1 mg daily, perform an endometrial biopsy and strongly consider switching to the sequential micronized progesterone regimen. American College of Endocrinology/Endocrine Society guideline – Grade A. 1
Conduct annual lipid profile and cardiovascular‑risk assessment for patients on synthetic progestins such as norethindrone acetate. American College of Endocrinology/Endocrine Society guideline – Grade A. 1

Do not use follicle‑stimulating hormone (FSH) levels to guide HRT adjustments; levels remain elevated despite adequate tissue action. American College of Endocrinology/Endocrine Society guideline – Grade A. 1
Do not delay endometrial evaluation when bleeding is heavy, prolonged (> 7 days), or occurs after 6–12 months of amenorrhea. American College of Endocrinology/Endocrine Society guideline – Grade A. 1
Do not prescribe compounded progesterone preparations lacking FDA oversight, as they have not demonstrated validated endometrial protection. American College of Endocrinology/Endocrine Society guideline – Grade A. 1